{"id":"cbd-powder-form-capsule","safety":{"commonSideEffects":["fatigue","diarrhea","changes in appetite","drowsiness"],"contraindications":["hypersensitivity to cannabidiol or formulation components"]},"_chembl":{"chemblId":"CHEMBL2109052","moleculeType":"Unknown"},"modality":"Small molecule","_dailymed":null,"mechanism":{"target":"Endocannabinoid system (CB1/CB2 receptors)","explanation":"Cannabidiol (CBD) modulates the endocannabinoid system through multiple pathways, including indirect effects on CB1 and CB2 receptors, as well as interactions with serotonin receptors, TRPV1 channels, and other targets. Unlike THC, CBD does not produce intoxicating effects and may have anti-inflammatory, anxiolytic, and neuroprotective properties.","oneSentence":"CBD interacts with the endocannabinoid system, primarily affecting CB1 and CB2 receptors, though its exact mechanism remains complex and not fully elucidated."},"_scrapedAt":"2026-03-28T05:56:53.667Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123259,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"cannabidiol oral solution","brand":"Epidiolex","company":"Greenwich Biosciences","rationale":"FDA-approved pharmaceutical-grade CBD for seizure disorders"},{"name":"nabiximols","brand":"Sativex","company":"GW Pharmaceuticals","rationale":"CBD/THC combination spray for spasticity and pain"},{"name":"dronabinol","brand":"Marinol","company":"AbbVie","rationale":"Synthetic cannabinoid for similar therapeutic applications"}],"description":"CBD powder form capsule is a cannabidiol-based investigational therapy being developed by Hadassah Medical Organization. Currently in Phase 1 clinical trials, this formulation delivers CBD in a standardized powder capsule format. The specific therapeutic indication and molecular targets are under investigation.","indications":{"approved":[{"status":"investigational","condition":"Unknown - Phase 1 investigation","patientPopulation":"Unknown"}]},"trialDetails":[{"nctId":"NCT03877991","phase":"EARLY_PHASE1","title":"Bioequivalence Assessment of Cannabidiol (CBD) Administrated in Oral Formulations","status":"UNKNOWN","sponsor":"Hadassah Medical Organization","startDate":"2024-02-19","conditions":"Pain","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cannabidiol solid dosage form"],"phase":"phase_1","status":"active","brandName":"CBD powder form capsule","genericName":"CBD powder form capsule","companyName":"Hadassah Medical Organization","companyId":"hadassah-medical-organization","firstApprovalDate":"","aiSummary":"CBD powder form capsules are being studied in clinical trials for pain management. The mechanism of CBD is currently unknown, according to ChEMBL.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}